Adaptimmune Therapeutics plc

ADP-A2AFP

Overview

Overview

Our ADP-A2AFP SPEAR T-cell product targets alpha-fetoprotein (AFP) is being investigated in an ongoing Phase I clinical trial for the treatment of patients with hepatocellular carcinoma (liver cancer).

Our Trials

C ompl e t ed sta g e * B ladde r , M elanoma, H ead & N eck, O v arian, N on-small c ell lung can c e r (NSC L C), E sopha g eal, G astric, S yn o vial sa r c oma, M R CLS ** S i t e specific p r o t o c ol amendme n t with MD A nde r son Can c e r C e n t e r M R CLS= m y x oid / r ound c ell liposa r c oma; H i T=HLA-independe n t T - c ell r e c e p t o r ( T CR) P hase 1 trial H ep a t o c ellula r ca r cinoma AD P -A2AF P AF P P r o g r am T he r a p y P r e Clinical P hase 1 P hase 2/3

Cancer indications in the ADP-A2AFP trial

Hepatocellular Cancer

Hepatocellular Cancer

Hepatocellular carcinoma makes up 80% of all cases of liver cancer.

Learn More

Publications

Review our findings and publications.

View ADP-A2AFP Publications View All Publications

Latest News

On April 2, 2019, we presented initial safety data from two patients with advanced hepatocellular carcinoma (HCC), liver cancer, from the first dose cohort of the ADP-A2AFP study at the annual AACR meeting. We did not observe clinically significant liver toxicity in the two patients treated at a dose of 100 million transduced cells, and these data supported dose escalation to the second cohort. Even though data are preliminary, we are encouraged by the evidence of tumor necrosis we saw in one of the two patients.

View Press Release